B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GLP1R

MOLECULAR TARGET

glucagon like peptide 1 receptor

UniProt: P43220NCBI Gene: 274016 compounds

GLP1R (glucagon like peptide 1 receptor) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GLP1R

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Liraglutide2.7715
2Levalbuterol0.691
3Semaglutide0.691
42-Methoxyestradiol0.691
5Levalbuterol0.691
6Azauridine0.691
7Clotrimazole0.691
8cycloheximide0.691
9Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.0.691
10Dihydroergotamine0.691
11Ethidium0.691
12Glucagon-Like Peptide 20.691
13Nortriptyline0.691
14Perphenazine0.691
15propionylpromazine hydrochloride0.691
16Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.0.691

About GLP1R as a Drug Target

GLP1R (glucagon like peptide 1 receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented GLP1R interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GLP1R inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.